首页|布地奈德联合氨溴索治疗新生儿吸入性肺炎的疗效

布地奈德联合氨溴索治疗新生儿吸入性肺炎的疗效

扫码查看
探讨布地奈德联合氨溴索治疗新生儿吸入性肺炎的疗效.方法 选取2015年1月~2016年1月绍兴市中心医院收治的新生儿吸入性肺炎患儿64例,随机分为对照组和研究组,各32例.对照组应用常规治疗,研究组应用布地奈德联合氨溴索治疗,比较2组患儿治疗结果.结果 研究组患儿呼吸困难、口唇发绀以及肺部啰音等症状的消失时间和住院时间明显短于对照组(P<0.01);研究组患儿治疗后白细胞介素(interleukin,IL)-6、IL-8以及肿瘤坏死因子α(tumor necrosis factor alpha,TNF-α)水平均明显低于对照组(P<0.05),治疗前2组患儿降钙素水平差异无统计学意义,治疗后3d、7d以及14d研究组的PCT明显低于对照组(P<0.05).结论 布地奈德联合氨溴索治疗新生儿吸入性肺炎,能够显著改善治疗效果,降低患儿的炎性因子水平,有利于患儿康复.
Clinical effect of budesonide combined with ambroxol in the treatment of neonatal aspiration pneumonia
Objective To evaluate the clinical efficacy of budesonide combined with ambroxol in the treatment of neonatal aspiration pneumonia.MethodsFrom January 2015 to January 2016 in our hospital 64 cases with neonatal aspiration pneumonia were randomly divided into two groups.The control group was treated with routine treatment, the study group used budesonide treatment, the treatment results were compared between the two groups.ResultsThe disappearance time of dyspnea, cyanosis, pulmonary rales and other symptoms and hospitalization time in study group were significantly shorter than those in the control group (P<0.01);the levels of interleukin(IL)-6, IL-8 and tumor necrosis factor alpha(TNF-α)in the study group after intervention were significantly lower than those in the control group (P<0.05) before treatment, PCT levels in two groups before treatment had no significant difference, three days, seven days and 14 days after the treatment PCT of the study group was significantly lower than the control group (P<0.05).ConclusionInhalation of budesonide and ambroxol in the treatment of neonatal pneumonia, can significantly improve the therapeutic effect, reduce the levels of inflammatory factors in children,can help the recovery of children.

aspiration pneumonianewbornbudesonideambroxol

姚和平

展开 >

绍兴市中心医院儿科,浙江绍兴312000

新生儿 吸入性肺炎 布地奈德 氨溴索

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.(5)
  • 2
  • 14